Clinical Trial

AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

Name: AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment — clinical trial record (NCT07158840)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AGA TKI NSCLC

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment

Trial Details

NCT Number	NCT07158840
Lead Sponsor	Akeso
Conditions	Non-Small Cell Lung Cancer
Enrollment	60 participants
Start Date	2025-09-05
Primary Completion	2028-09 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2025-09-08